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Background: Although there have been several reports in which
central nervous system (CNS) metastases of non-small cell lung
cancer (NSCLC) were improved by erlotinib, cerebrospinal fluid
(CSF) penetration of erlotinib in such patients has not been reported.
We investigated CSF concentrations of erlotinib and its active
metabolite OSI-420.
Method: We administered 150 mg erlotinib daily to four patients
with NSCLC who had CNS metastases, and we investigated plasma
pharmacokinetics of erlotinib and OSI-420 on days 1 and 8. In
addition, we measured the concentrations of erlotinib and OSI-420
in CSF just before administration of erlotinib on day 8.
Results: In all cases except for one case, plasma pharmacokinetics
data on day 8 were similar to those previously reported. The mean
SD CSF concentrations of erlotinib and OSI-420 were 54  30
ng/ml and 10.8  8.2 ng/ml, respectively. The mean  SD CSF
penetration rates of erlotinib and OSI-420 were 5.1%  1.9% and
5.8%  3.6%, respectively. CSF concentrations of erlotinib ex-
ceeded median inhibitory concentration (IC50) of erlotinib in intact
tumor cells with wild-type epidermal growth factor receptor gene.
Conclusion: The CSF penetrations of erlotinib and OSI-420 in
patients with NSCLC who had CNS metastases were approximately
5.1% and 5.8%, respectively. This indicates that erlotinib can
become a treatment option for CNS metastases of NSCLC.
Key Words: Erlotinib, Non-small cell lung cancer, Cerebrospinal
fluid, Brain metastasis, Carcinomatous meningitis.
(J Thorac Oncol. 2010;5: 950–955)
The epidermal growth factor receptor (EGFR) is recog-nized as an important molecular target in cancer therapy.1
Erlotinib is an orally active and selective tyrosine kinase
inhibitor of the EGFR (EGFR-TKI) that has demonstrated
antitumor activity in patients with non-small cell lung cancer
(NSCLC).2
Patients with central nervous system (CNS) metastases
in general suffer from deterioration of performance status
(PS) and therefore do not have a long survival time. The
primary treatment for CNS metastases in patients with
NSCLC has traditionally consisted of whole-brain radiother-
apy, surgery, or radiosurgery, whereas systemic chemother-
apy has been thought to play a limited role because of the
belief that the brain is a pharmacologic sanctuary site.3,4
However, several studies have documented the effectiveness
of gefitinib, another EGFR-TKI, in the treatment of CNS
metastases of NSCLC.5–15 There is also an article in which
CNS metastases of NSCLC were improved by high-dose
gefitinib.16 In addition, several recent articles documented
that CNS metastases were improved by erlotinib.17–22 How-
ever, very little is known about the CNS penetration and
exposure to this drug.23–25 Broniscer et al.23 reported on the
CNS penetration and exposure to erlotinib in a child’s case
with glioblastoma; however, cerebrospinal fluid (CSF) pene-
tration of erlotinib in adult patients with NSCLC who had
CNS metastases has never been reported.
Herein, 150 mg erlotinib was administered daily to four
patients with NSCLC who had CNS metastases, and we




Clinical characteristics of all patients are summarized
in Table 1. All patients had poor PS due to CNS metastases.
The histology of all patients was adenocarcinoma. Only case
4 had an EGFR gene mutation (single-point mutation in exon
21; L858R); however, in case 1, the mutations were not
evaluated. Previous treatment of cases 1 and 4 included
gefitinib and their disease control terms were 9 and 7 months,
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respectively. Cases 1 and 3 previously received whole-brain
radiotherapy. Phenytoin (PHT) was administered to case 4
because she went into convulsions due to brain metastases.
Plasma Pharmacokinetic Analysis of Erlotinib
and OSI-420
We performed plasma pharmacokinetic (PK) analysis
of erlotinib and OSI-420 on days 1 and 8 after starting
administration of erlotinib. Blood samples were obtained at 5
points a day, i.e., just before administration (Cplasma0), 2
hours (Cplasma2), 4 hours (Cplasma4), 8 hours (Cplasma8), and
24 hours (Cplasma24) after administration. In case 1, CSF
samples were obtained at 2 hours after administration (CCSF2)
on day 1 and just before administration (CCSF0) on day 8. In
cases 2, 3, and 4, CSF samples were obtained at CCSF0 on day
8. The concentrations were determined by high-performance
liquid chromatography with ultraviolet detection as previ-
ously reported.26 Before collection of samples and analysis,
we got written informed consent from all four patients.
RESULTS
Case 1
On day 1, the maximal plasma concentration (Cmax) of
erlotinib was 802 ng/ml at Cplasma8 and Cmax of OSI-420 was
53 ng/ml at Cplasma4. Cplasma24 dropped to 437 and 28 ng/ml,
respectively (Figure 1). The area under the plasma drug
concentration-time curve from 0 to 24 hours (AUC0–24) of
erlotinib was 14,210 ng h/ml and AUC0–24 of OSI-420 was
893 ng h/ml (Table 2).
On day 8, Cplasma0 of erlotinib was 895 ng/ml and
Cplasma0 of OSI-420 was 58 ng/ml. Cmax was 1850 ng/ml at
Cplasma2 and 126 ng/ml at Cplasma4, respectively. Cplasma24
dropped to 1057 and 80 ng/ml, respectively (Figure 1).
AUC0–24 of erlotinib was 33,441 ng  h/ml and AUC0–24 of
OSI-420 was 2465 ng  h/ml (Table 2). These PK data were
similar to those previously reported.27
On day 1, CCSF2 of both erlotinib and OSI-420 were
lower than the limits of quantitation, i.e., lower than 2 ng/ml.
On day 8, CCSF0 of erlotinib was 42 ng/ml and CCSF0 of
OSI-420 was 4.7 ng/ml. The penetration rate of erlotinib was
4.7% and that of OSI-420 was 8.1% (Table 3).
A few days after starting administration of erlotinib, her
symptoms improved and ECOG PS recovered to 2. Four
weeks after administration, the signs of brain metastases and
carcinomatous meningitis on the brain magnetic resonance
imaging (MRI) also improved (partial response) (Figure 2B).
Case 2
On day 1, Cmax of erlotinib was 1724 ng/ml at Cplasma8
and Cmax of OSI-420 was 111 ng/ml at Cplasma8. Cplasma24
dropped to 1280 and 72 ng/ml, respectively (Figure 3).
AUC0–24 of erlotinib was 32,178 ng  h/ml and AUC0–24 of
OSI-420 was 2022 ng  h/ml (Table 2).
On day 8, Cplasma0 of erlotinib was 1745 ng/ml and
Cplasma0 of OSI-420 was 239 ng/ml. Cmax was 2889 ng/ml at
Cplasma4 and 341 ng/ml at Cplasma4, respectively. Cplasma24
dropped to 1660 and 244 ng/ml, respectively (Figure 3).
AUC0–24 of erlotinib was 51,351 ng  h/ml and AUC0–24 of
OSI-420 was 7145 ng  h/ml (Table 2). Although the PK data
on day 1 were a little different from those previously re-
ported, the PK data on day 8 were similar to those previously
reported.27
On day 8, CCSF0 of erlotinib was 87 ng/ml and CCSF0
of OSI-420 was 22.3 ng/ml. The penetration rate of erlotinib
was 5.0% and that of OSI-420 was 9.3% (Table 3).
Although her symptoms improved a few days after
starting administration of erlotinib and her ECOG PS recov-
ered to 3, 4 weeks after starting administration, the signs of
brain metastases on brain MRI had not been obviously
improved (stable disease) (Figure 2D).
Case 3
On day 1, Cmax of erlotinib was 3075 ng/ml at Cplasma4
and Cmax of OSI-420 was 409 ng/ml at Cplasma8. Cplasma24
dropped to 1190 and 276 ng/ml, respectively (Figure 4).
FIGURE 1. Plasma concentration-time plots of erlotinib and
OSI-420 in case 1 on days 1 and 8. Arrows indicate 150 mg
erlotinib administration.
TABLE 1. Clinical Characteristics of the Patients
Case Age (yr) Sex PS Histology EGFR Gene Stage Smoking Status Previous Treatment
1 59 F 3 Ad NE cT4N3M1 Never Three chemotherapies and WBRT
2 82 F 4 Ad Wild type cT2N2M1 Never No
3 70 F 3 Ad Wild type cT1N3M1 Never One chemotherapy and WBRT
4 86 F 3 Ad Ex 21; L858R cT4N0M1 Never One chemotherapy
PS, performance status; EGFR, epidermal growth factor receptor; Ad, adenocarcinoma; Never, never-smoker; WBRT, whole-brain radiotherapy; NE, not evaluated.
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AUC0–24 of erlotinib was 47,176 ng  h/ml and AUC0–24 of
OSI-420 was 7620 ng  h/ml (Table 2).
On day 8, Cplasma0 of erlotinib was 2116 ng/ml and
Cplasma0 of OSI-420 was 731 ng/ml. Cmax was 3200 ng/ml at
Cplasma4 and 1006 ng/ml at Cplasma2, respectively. Cplasma24
dropped to 2334 and 826 ng/ml, respectively (Figure 4).
AUC0–24 of erlotinib was 61,093 ng  h/ml and AUC0–24 of
OSI-420 was 20,931 ng  h/ml (Table 2). Although the PK
data on day 1 were different from those previously reported,
the PK data on day 8 were similar to those previously
reported.27
On day 8, CCSF0 of erlotinib was 67 ng/ml and CCSF0
of OSI-420 was 11.1 ng/ml. The penetration rate of erlotinib
was 3.2% and that of OSI-420 was 1.5% (Table 3).
After starting administration of erlotinib, her symptoms
improved and ECOG PS recovered to 2. Four weeks after
starting administration of erlotinib, the signs of brain metas-
tases on brain MRI improved (partial response) (Figure 2F)
and serum carcinoembryonic antigen decreased to 172.8
ng/ml from 629.6 ng/ml.
Case 4
On day 1, Cmax of erlotinib was 479 ng/ml at Cplasma2
and Cmax of OSI-420 was 80 ng/ml at Cplasma4. Cplasma24
dropped to 238 and 40 ng/ml, respectively (Figure 5).
AUC0–24 of erlotinib was 8045 ng  h/ml and AUC0–24 of
OSI-420 was 1452 ng  h/ml (Table 2).
On day 8, Cplasma0 of erlotinib was 234 ng/ml and
Cplasma0 of OSI-420 was 113 ng/ml. Cmax was 809 and 304
ng/ml at Cplasma2, respectively. Cplasma24 dropped to 291 and
109 ng/ml, respectively (Figure 5). AUC0–24 of erlotinib was
9853 ng  h/ml and AUC0–24 of OSI-420 was 4113 ng  h/ml
(Table 2). The PK data on day 8 tended to be lower than those
previously reported.27 On day 8, CCSF0 of erlotinib was 18
ng/ml and CCSF0 of OSI-420 was 5 ng/ml. The penetration
rate of erlotinib was 7.7% and that of OSI-420 was 4.4%
(Table 3). Four weeks after starting administration of erlo-
tinib, the signs of brain metastases on brain MRI slightly
improved (stable disease) (Figure 2H).
As summarized in Table 3, the mean  SD CSF
concentrations of erlotinib and OSI-420 were 54  30 ng/ml
and 10.8  8.2 ng/ml, respectively. The mean  SD CSF
penetration rates of erlotinib and OSI-420 were 5.1% 1.9%
and 5.8%  3.6%, respectively.
DISCUSSION
In this article, we investigated the CSF concentrations
and penetration rates of erlotinib and OSI-420 on day 8 when
steady-state plasma concentrations of erlotinib were assumed
TABLE 2. Plasma Pharmacokinetics Parameters of Erlotinib and OSI-420
Case Day
Erlotinib OSI-420
AUC0–24 (ng  h/ml) Cmax (ng/ml) AUC0–24 (ng h/ml) Cmax (ng/ml)
1 1 14,210 802 893 53
8 33,441 1850 2465 126
2 1 32,178 1724 2022 111
8 51,351 2889 7145 341
3 1 47,176 3075 7620 409
8 61,093 3200 20,931 1006
4 1 8045 479 1452 80
8 9853 809 4113 304
Previous 1 12,845.48  3774.53 958.00  457.19 789.6  300.8 62.7  41.4
23 42,678.50  20,434.75 2384.33  932.43 NE NE
AUC0–24, area under the plasma drug concentration-time curve from 0 to 24 h; Cmax, maximal plasma concentration; NE, not evaluated;
Previous, patients reported in Japanese phase I study.27
TABLE 3. Cerebrospinal Fluid Concentrations of Erlotinib and OSI-420 on Day 8, Tumor
Response, and Change of PS
Case
Erlotinib OSI-420
Tumor Response Change of PSCCSF0 (ng/ml)
CCSF0:
Cplasma0 (%) CCSF0 (ng/ml)
CCSF0:
Cplasma0 (%)
1 42 4.7 4.7 8.1 Partial response 33 2
2 87 5.0 22.3 9.3 Stable disease 43 3
3 67 3.2 11.1 1.5 Partial response 33 2
4 18 7.7 5 4.4 Stable disease 33 3
Mean  SD 54  30 5.1  1.9 10.8  8.2 5.8  3.6
CSF, cerebrospinal fluid; CCSF0, CSF concentration just before administration of erlotinib; Cplasma0, CSF concentration just before
administration of erlotinib; PS, performance status.
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FIGURE 2. Brain magnetic resonance imaging (MRI) of the patients. In case 1, the signs of central nervous system (CNS)
metastases (arrows) were revealed before administration of erlotinib (A). Four weeks after initiation of erlotinib, the signs (ar-
rows) had improved (B). In case 2, the signs of CNS metastases (arrows) were revealed before administration of erlotinib (C).
Four weeks after initiation of erlotinib, the signs (arrows) had not obviously improved although there was a lot of motion arti-
fact (D). In case 3, the signs of CNS metastases (arrows) were revealed before administration of erlotinib (E). Four weeks after
initiation of erlotinib, the signs (arrows) had improved (F). In case 4, the signs of CNS metastases (arrows) were revealed be-
fore administration of erlotinib (G). Four weeks after initiation of erlotinib, the signs (arrows) had slightly improved (H).
FIGURE 3. Plasma concentration-time plots of erlotinib and
OSI-420 in case 2 on days 1 and 8. Arrows indicate 150 mg
erlotinib administration.
FIGURE 4. Plasma concentration-time plots of erlotinib and
OSI-420 in case 3 on days 1 and 8. Arrows indicate 150 mg
erlotinib administration.
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to be achieved. The mean  SD CSF concentrations of
erlotinib and OSI-420 were 54  30 ng/ml and 10.8  8.2
ng/ml, respectively. The mean SD CSF penetration rates of
erlotinib and OSI-420 were 5.1%  1.9% and 5.8%  3.6%,
respectively.
In all cases except for case 4, the plasma PK data on
day 8 were similar to those previously reported.27 However,
the plasma PK data on day 1 were different from each other
and from those previously reported.27 Because erlotinib is an
orally active agent, there seems to be differences among
individuals in the absorption and the metabolism of erlotinib,
which may be affected by age, other drugs, or genetic
polymorphism. The plasma PK data on day 1 seemed to be
especially affected by these differences. In case 4, PHT was
administered to the patient. PHT is one of the CYP3A4
inducers that increase erlotinib metabolism, thus decreasing
the plasma exposure.28 This is thought to be the reason that
the PK data tended to be lower.
In case 1, CCSF2 of both erlotinib and OSI-420 on day 1
were lower than limits of quantitation. This might indicate that
little erlotinib and OSI-420 penetrated to CSF in 2 hours.
However, Cplasma2 of both erlotinib and OSI-420 on day 1
tended to be low, i.e., her absorption of erlotinib was poor on day
1, which might affect her low CCSF2 on day 1. On day 8, when
steady-state plasma concentrations of erlotinib were assumed to
be achieved, the mean  SD CSF penetration rates of erlotinib
and OSI-420 were 5.1%  1.9% and 5.8%  3.6%, respec-
tively. These differences in the concentrations between plasma
and CSF are thought to be associated with the blood-brain
barrier (BBB). These penetration rates tended to be a little higher
than those of normal nonhuman primates that were previously
reported.23,25 This indicated that erlotinib tended to penetrate
more into the CSF in patients with brain lesions. These obser-
vations are thought to be dependent on a combination of the
degree of disruption of the BBB caused by tumor invasion.29 In
contrast, the penetration rates tended to be lower than that of the
child’s case with glioblastoma, which was previously reported,
although this child’s case is similar to our cases in that both had
brain lesions.23 This may be explained by the effect of menin-
geal inflammation due to Streptococcus viridans meningitis,
which is known to enhance the CSF penetration of nonlipophilic
anti-infective drugs. In terms of the efficacy to brain metastases,
because the BBB is commonly disrupted in the cases with brain
metastases, it would be reasonable to assume that erlotinib
penetration would be higher within these tumors than in CSF,
which may be a reason for the good clinical response to brain
metastases.
As seen in case 1, several cases in which erlotinib im-
proved CNS metastases resistant to gefitinib have been report-
ed.20 Gefitinib and erlotinib are similar anilinoquinazoline com-
pounds. Although it seems that erlotinib has a slightly broader
spectrum of kinase inhibition than gefitinib,20 they are essen-
tially EGFR-specific TKIs. The most prominent difference be-
tween these two drugs is the dose setting. Although the approved
daily dose of erlotinib (150 mg) is equal to the maximal tolerated
dose of erlotinib, the daily dose of gefitinib was set at 250 mg,
approximately one-third of the maximal tolerated dose of ge-
fitinib. Katayama et al.20 suggest that this might be why erlotinib
improved CNS metastases resistant to gefitinib. Unfortunately,
20 to 50% of patients with clinical or biologic predictors for
EGFR-TKI sensitivity are resistant to the drug (primary or de
novo resistance), and although the majority initially shows a
good clinical response, drug resistance invariably occurs and
disease progresses (acquired resistance). A secondary EGFR
gene mutation (T790M) was found in 50% of patients relapsing
after an initial response30 and, more recently, another secondary
mutation (D761Y) was found in a brain metastasis of a lung
cancer patient initially responsive to gefitinib.31 Two recent
studies revealed amplification of the MET oncogene in 20% of
patients with acquired resistance.32,33 However, some cases
revealed a good clinical response to erlotinib in the setting of
acquired resistance with brain metastases, and the mechanism of
acquired resistance to gefitinib could not be fully applied to the
erlotinib cases.
In our cases, the erlotinib penetration rate to CSF was
approximately 5% and, CCSF0 on day 8 of erlotinib exceeded the
median inhibitory concentration (IC50) of erlotinib in intact
tumor cells with wild-type EGFR gene (20 nmol/l; 7.9 ng/ml).34
In contrast, the gefitinib penetration rate to CSF was reported to
be less than 1%, and gefitinib CSF concentration did not exceed
the IC50 of gefitinib when 250 mg gefitinib was administered
daily.7,16 There seems to be differences among the penetration
rates of gefitinib, erlotinib, and OSI-420. A major protein con-
stituent of the BBB is P-glycoprotein (P-gp), which pumps
natural product chemotherapy drugs and toxins out of the
CNS.35 These penetration differences may be dependent on the
affinity of different drugs for P-gp. There is a possibility that
erlotinib is more effective for CNS metastases than gefitinib and
is effective for CNS metastases even in cases with wild-type
EGFR genes because the penetration rate of erlotinib into the
CSF can be higher than that of gefitinib, and the CSF concen-
tration of erlotinib can exceed the IC50 of erlotinib in intact
tumor cells with wild-type EGFR gene. In fact, erlotinib im-
proved CNS metastases resistant to gefitinib in case 1, and
erlotinib improved CNS metastases with wild-type EGFR gene
in case 3.
FIGURE 5. Plasma concentration-time plots of erlotinib and
OSI-420 in case 4 on days 1 and 8. Arrows indicate 150 mg
erlotinib administration.
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A study in which EGFR gene mutation-positive patients
with extremely poor PS benefit from first-line gefitinib has been
reported.36 In this article, 11 of the 29 patients had CNS metas-
tases. From our data, erlotinib can be more effective for CNS
metastases than gefitinib and can be effective even in EGFR
gene wild-type cases. Therefore, erlotinib treatment, which can
be administered to a patient with poor PS, should be considered
even if patients have poor PS due to CNS metastases.
In conclusion, erlotinib treatment can be more effective
for CNS metastases of NSCLC than gefitinib and can be effec-
tive for CNS metastases even in EGFR gene wild-type cases
because the penetration rate of erlotinib can be higher than that
of gefitinib and CSF concentration can exceed the IC50 of
erlotinib with wild-type EGFR gene. Therefore, even if CNS
metastases are resistant to gefitinib or EGFR gene are wild type,
erlotinib can become a treatment option. Moreover, erlotinib
should be considered as a treatment option for NSCLC patients
with CNS metastases even if patients have poor PS due to CNS
metastases because it is possible that the PS can be recovered by
erlotinib treatment. All four patients treated in this study were of
an Asian ethnicity. Therefore, generalization to Caucasian pop-
ulation may be difficult in terms of the differences in PK,
metabolism, CNS transport/penetration, or underlying polymor-
phisms for the transport of CNS penetration of erlotinib. How-
ever, there has not yet been a trial of erlotinib treatment for CNS
metastases of NSCLC. To assess the effectiveness of erlotinib
for CNS metastases of NSCLC, further study is required.
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